Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study
This purpose of this study it to characterize the walking patterns of children diagnosed with Acute Lymphoblastic Leukemia (ALL)and Lymphoblastic Lymphoma (LL) at different times in the treatment protocol and after completion of treatment. Their walking patterns will be compared to children without ALL or LL to see if their walking patterns are different at specific times in their treatment program or up to 10 years after completion of their treatment. The investigators will gather data by observing how the child walks, runs, hops on one foot and climbs stairs and by recording walking patterns on a pressure sensitive mat. The investigators will compare this data to children without ALL and LL.
Acute Lymphoblastic Leukemia
Childhood Lymphoblastic Lymphoma
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Temporal and Spatial Gait Parameters of Children Undergoing Treatment for and Surviving Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma|
- Pediatric Quality of Life Questionnaire [ Time Frame: At one of the 10 specific time points in therapy or at years 1,3,5 and 10 years off therapy (+/- 1 year) ] [ Designated as safety issue: No ]A 23 question questionnaire addressing concerns in the area of physical activity, feelings, getting along with others and problems with work or studies.
- Global Gait Score [ Time Frame: At one of the 10 specific time points in therapy or at years 1,3,5 and 10 years off therapy (+/- 1 year) ] [ Designated as safety issue: No ]Childrens' ability to walk, run, hop on one leg, climb stairs will be observed and scored based on a 0-4 scale. O will indicate one skill that is not normal, a 2 will indicate 2 skills, 3 will indicate 3 skills and a 4 will indicate 4 skills that are not normal
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Children with ALL or LL
Children diagnosed with ALL or LL will be recruited for this study
Cases will be identified and referred by the primary oncologist or by the Childhood Cancer Survivorship team. When a possible subject has been identified they will be contacted via telephone or during a routine clinic visit to determine their interest in the study. Two hundred subjects will be recruited for participation with the goal of 5-10 subjects at each of the 14 times points across the treatment protocol and survivorship. These time points to include: at diagnosis, the start of consolidation therapy, the start of interim maintenance therapy, the start of delayed intensification therapy, Day 29 of delayed intensification therapy, the start of interim maintenance II therapy (if applicable), Day 1 of cycle 1,3,5 of maintenance therapy, end of therapy, and 1, 3, 5, and 10 years off therapy ( +/-1 year).
Clinical data will be collected from the medical record, roadmaps documenting cancer-directed therapy, direct patient interview and examination by the physical therapist during the study evaluation. Clinical data will include: Date of birth (to calculate age at diagnosis and current age); Gender; Race and Ethnicity; Primary cancer diagnosis; Date of Primary Cancer Diagnosis; Chemotherapeutic agents received (agent name, cumulative dose and date received); Radiation therapy (date received, site radiated, and dose delivered); Any other clinical conditions affecting musculoskeletal performance; Dates of previous PT; Pain score at the time of study participation. Height, weight, shoe size and leg length will be collected at time of study participation.
Subjects will complete a self report of the PedsQL™ Generic Core Scale and the parents will complete the parental report.
Observation gait assessment will include hopping on one foot, running and walking 30' and ascending/descending stairs.
Temporal spatial gait parameters will be recorded on the GaitRite mat
|United States, Oregon|
|Doernbecher Children Hospital|
|Portland, Oregon, United States, 97239|
|Study Director:||Susan Lindemulde, MD, MCR||Oregon Health and Science University|